Literature DB >> 1663589

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai.

C Schudt1, S Winder, S Forderkunz, A Hatzelmann, V Ullrich.   

Abstract

Chromatographic analysis of 3',5'-cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the cytosol of human neutrophils shows the predominant presence of PDE IV (cAMP specific) and PDE V (cGMP specific). PDE IV is characterized by (1) cAMP selectivity, (2) a KM for cAMP of 1.2 microM and (3) a typical rank order of IC50-values for PDE inhibitors: 0.13, 0.17, 47 and 9.5 microM for PDE IV selective rolipram, PDE III/IV selective zardaverine, PDE III selective motapizone and unselective 3-isobutyl-1-methylxanthine (IBMX), respectively. Functions of polymorphonuclear leukocytes (PMN) such as N-formylmethionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide release and fMLP/thimerosal elicited leukotriene (LT) biosynthesis are inhibited by these PDE inhibitors with the same rank order and even lower IC50-values. Measurements of changes in cytosolic Cai in Fura-2 loaded PMN demonstrate a transient Cai increase after stimulation with 0.1 microM fMLP and an additional sustained elevation of Cai levels in the presence of thimerosal. PDE inhibitors suppress this sustained phase of Cai release with the same rank order of IC50-values as LT biosynthesis. The correlation between fMLP/thimerosal-induced LT biosynthesis and Cai levels reveal a Cai threshold of 150 nM for arachidonic acid metabolism. cAMP levels in PMN were elevated by PDE inhibitors alone by less than 2-fold. In the presence of fMLP however, cAMP was increased up to 10-fold and the efficacy of PDE inhibitors to increase cAMP paralleled their potency to inhibit PDE IV.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663589     DOI: 10.1007/bf00174752

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes.

Authors:  A Hatzelmann; V Ullrich
Journal:  Eur J Biochem       Date:  1987-11-16

2.  Chemoattractant-elicited alterations of cAMP levels in human polymorphonuclear leukocytes require a Ca2+-dependent mechanism which is independent of transmembrane activation of adenylate cyclase.

Authors:  M W Verghese; K Fox; L C McPhail; R Snyderman
Journal:  J Biol Chem       Date:  1985-06-10       Impact factor: 5.157

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolated airway smooth muscle.

Authors:  S E Bryson; I W Rodger
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

Review 5.  Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma.

Authors:  F A Kuehl; M E Zanetti; D D Soderman; D K Miller; E A Ham
Journal:  Am Rev Respir Dis       Date:  1987-07

6.  Inhibitory effect of prostaglandin E2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils.

Authors:  T Takenawa; J Ishitoya; Y Nagai
Journal:  J Biol Chem       Date:  1986-01-25       Impact factor: 5.157

7.  Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors.

Authors:  S Nourshargh; J R Hoult
Journal:  Eur J Pharmacol       Date:  1986-03-18       Impact factor: 4.432

8.  The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.

Authors:  K J Murray; P J England; T J Hallam; J Maguire; K Moores; M L Reeves; A W Simpson; T J Rink
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

9.  The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides.

Authors:  V Di Marzo; J R Tippins; H R Morris
Journal:  Eur J Pharmacol       Date:  1989-03-14       Impact factor: 4.432

10.  Evidence that the functional responses of human neutrophils occur independently of transient elevations in cyclic AMP levels.

Authors:  L Simchowitz; I Spilberg; J P Atkinson
Journal:  J Cyclic Nucleotide Protein Phosphor Res       Date:  1983
View more
  27 in total

1.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.

Authors:  M Grous; M Barnette
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

Review 3.  New therapies for chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

4.  Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

Authors:  J Cortijo; V Villagrasa; C Navarrete; C Sanz; L Berto; A Michel; P A Bonnet; E J Morcillo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 5.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

6.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Anti-oxidative effects of theophylline on human neutrophils involve cyclic nucleotides and protein kinase A.

Authors:  A G Mahomed; A J Theron; R Anderson; C Feldman
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

8.  Effect of two phenanthrene alkaloids on angiotensin II-induced leukocyte-endothelial cell interactions in vivo.

Authors:  Rossana Estellés; Javier López-Martín; Lara Milian; José-Enrique O'Connor; Magdalena Martínez-Losa; Miguel Cerdá-Nicolás; Edet M Anam; María Dolores Ivorra; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Maria Amparo Blázquez; Maria-Jesús Sanz
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

9.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

10.  Inhibition of HA synthase 3 mRNA expression, with a phosphodiesterase 3 inhibitor, blocks lung injury in a septic ventilated rat model.

Authors:  Hicham Mrabat; John Beagle; Zhao Hang; Hari G Garg; Charles A Hales; Deborah A Quinn
Journal:  Lung       Date:  2009-07-02       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.